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VI Comparative Safety and Immunogenicity of an 
Acellular versus Whole-Cell Pertussis Component 
of Diphtheria-Tetanus-Pertussis Vaccines in 
Senegalese Infants 
A diphtheria and tetanus toxoid two-component acellular pertussis vaccine (DTaP), con- 
sisting of 25 yg glutaraldehyde-detoxified pertussis toxin (PT) and 25 pg native filamen- 
tous hemagglutinin (FHA), was compared with diphtheria and tetanus toxoid whole-cell 
pertussis vaccine (DTwP) in a randomized, double-blind manner in 286 Senegalese 
infants inoculated at two, four, and six months of age. In infants receiving DTaP a sig- 
nificantly lower rate of local reactions, crying and fever was observed than in infants 
receiving DTwP. One month after the third dose, the geometric mean titres for FHA 
antibodies were higher in the DTaP group, whereas increases in PT antibody titres were 
higher in the DTwP group. More than 90% of the infants had a fourfold or more increase 
in antibodies to both PT and FHA with either vaccine. Diphtheria, tetanus, and polio 
antibody responses were also measured and found to be comparable between the two 
groups. The results of this pilot study support the implementation of a field trial to com- 
pare the protective efficacy of these vaccines against pertussis in the same setting. 
The development of highly purified acellular per- 
tussis vaccines has been driven by concern over ad- 
verse reactions associated with conventional vac- 
cines and the need for long-term protection. Re- 
vaccination of older children and young adults is 
now being seriously considered but is only accept- 
able if better-tolerated vaccines are available. 
The efficacy of the acellular pertussis vaccines 
demonstrated in recent trials conducted in Europe 
favours their widespread use (14). 
The same concerns are shared in developing 
countries (5,6) considering the adoption of acel- 
lular pertussis vaccines. These considerations and 
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suggestions that the immune response in African 
children may differ from that in Caucasian chil- 
dren (7), emphasize the need to compare acellu- 
lar and whole-cell vaccines in the specific setting 
of developing countries. 
The objectives of this study were to assess in 
Senegalese children the safety of a diphtheria- 
tetanus acellular pertussis vaccine (DTaP) com- 
pared with a diphtheria-tetanus whole-cell pertus- 
sis vaccine (DTwP), to study the immunogenicity 
of each component of the DTP vaccine, and to 
study the immunogenicity of the enhanced-poten- 
cy inactivated polio vaccine routinely used in this 
region of Africa. This study preceded implemen- 
tation of a field trial to compare the protective ef- 
ficacy of these vaccines against pertussis in the 
same setting. 
Materials and Methods 
DT Acellular Pertussis Vaccine (DTaP). DTaP (Lot S2112, 
Pasteur Mérieux, France) consisted of 25 pg of glutaralde- 
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Table 1: Number of infants who were recruited for the trial and who were analysed for safety and immunogenicity. 
Dose 1 Dose 2 Dose 3 
n Percent Mean Mean n Percent Mean Mean n Percent Mean Mean 
female age weight female age weight female age weight 
(months) (kg) (months) (kg) (months) (kg) 
Randomisation 
DTwP 145 52 3.1 5.4 123 53 5.1 6.4 107 51 7.1 6.9 
DTaP 141 51 3.1 5.4 122 53 5.1 6.4 109 51 7.2 7.0 
DTwP 118 55 3.0 5.5 87 53 5.0 6.5 80 55 7.0 7.1 
DTaP 123 51 3.0 5.5 96 50 5.0 6.5 87 50 7.0 7.0 
Safety analysis 
Immunogenicity 
analysis 
Pertussis 
toxin 
DTwP 39 56 2.9 5.4 39 56 4.8 6.4 39 56 6.9 7.0 
DTaP 57 47 3.0 5.5 57 47 4.9 6.4 57 47 6.9 7.1 
Filamentous 
haemagglutinin 
DTwP 28 54 2.9 5.6 28 54 4.8 6.5 28 54 6.9 7.1 
DTaP 40 40 3.0 5.5 40 40 4.9 6.4 40 40 6.9 7.1 
hyde-detoxified pertussis toxin (PT), 25 pg of native filamen- 
tous hemagglutinin (FHA), at least 30 IU of purified diphthe- 
ria toxoid, and 40 IU of purified tetanus toxoid per 0.5 ml 
dose adsorbed on aluminium hydroxide (aluminium content 
0.29 to 0.61 mg per 0.5 ml dose). 
DT Whole-Cell Pertussis Vaccine (D TwP}. Conventional per- 
tussis vaccine from a single lot (Pasteur Mérieux) contained 
at least 4 IU of heat-inactivated pertussis vaccine, in accor- 
dance with WHO and European Pharmacopeia requirements, 
at least 30 IU of purified diphtheria toxoid, and 60 IU of pur- 
ified tetanus toxoid per 0.5 ml dose mixed in the presence of 
aluminium hydroxide (aluminium content 0.54 to 0.65 mg per 
0.5 ml dose). 
Polio Vaccine. The enhanced-potency inactivated polio vac- 
cine (IPV) was produced by Pasteur Mérieux. Each 0.5 ml 
dose ready-to-use syringe contained 40, 8, and 32 antigen 
units of polio types 1,2, and 3, respectively. 
Study Population. The study was conducted in Niakhar, Sene- 
gal, a rural farming area 150 km from Dakar. The population 
of approximately 27,000 has been followed up since 1983 in 
demographic and health studies (8,9). 
Vaccinations. Vaccines were administered in monthly sessions 
organized at vaccination clinics. Eligible infants were sum- 
moned to the vaccination session, and those whose parents 
agreed were vaccinated. The infants received three injections 
of vaccine at 2 to 3,4 to 5, and 6 to 7 months of age following 
this schedule: BCG, DTP1, and IPVl(2-3 months); DTP2 and 
IPV2 (4-5 months); DTP3, IPV3, measles, and yellow fever 
(6-7 months). DTaP and DTwP were randomly assigned in a 
double-blind manner according to a computerized list by 
blocks of ten. Vaccines were injected intramuscularly, DTP in 
the right thigh and IPV in the left thigh. 
Reaction Assessment. To assess local and systemic reactions, 
infants were visited at home by a physician within 48 to 72 
hours of vaccination. Clinical examination was performed by 
one of three physicians after training, and data were recorded 
on a standardized form.The body temperature was measured, 
and the injection site examined for redness, induration orten- 
derness. A general clinical examination was performed, and 
the mother was questioned about signs of a moderate reac- 
tion, (such as anorexia, vomiting, restlessness, sleepiness, irri- 
tability or crying), or signs of a severe reaction, (such as per- 
sistent or high-pitched crying, seizure or hypotonia). Indura- 
tion and redness was recorded only if 3 cm or more in 
diameter.Al1 deaths were reported and assessed as part of the 
demographic registration system by the verbal autopsy meth- 
od in which field workers interviewed parents in order to 
complete certificates; the likely cause of death was indepen- 
dently assessed retrospectively by two physicians. 
Serological Assays. Serum samples were obtained by finger- 
prick before the first and third vaccinations and one month 
after the third vaccination. Micro-containers with serum sep- 
arators were centrifuged at the field station and the serum 
stored at -20°C. All subsequent assays were performed at 
Pasteur Mérieux in France. Antibodies to PT were measured 
in duplicate by the Chinese hamster ovary (CHO) cell toxin- 
neutralization method (IO, 11). Results were expressed as the 
reciprocal of the endpoint dilution, the lower limit of detec- 
tion being set at a 1 2  dilution. IgG antibodies to FHA were 
measured in triplicate in an enzyme immunoassay (EIA) 
(12). Results were expressed in EIA units per milliliter by 
comparison with an internal reference serum. Tetanus and 
diphtheria antibody titres were determined by radioimmu- 
noassay and expressed as international units per milliliter 
(IU/ml). Polio type I and III antibody titres were determined 
by a seroneutralisation test. For all antigens, seroconversion 
was defined as a fourfold increase above the pre-vaccination 
level. For diphtheria and tetanus, serum-levels of 2 0.05 
IU/ml were considered to indicate protection. For polio types 
I and III, neutralizing antibody titres at a dilution of 2 1:5 
were considered to indicate protection. 
Statistical Analysis. Differences in reaction rates between the 
groups were tested by the two-tailed chi-square and two- 
tailed Fisher exact tests, when indicated. The chi-square test 
for trend was used to test for a trend in adverse reactions in 
the sequence of doses. Serological data calculations were per- 
formed on logarithmically transformed data, reporting the 
antilogarithm. Within groups, comparisons were made by the 
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Table 2 Local and systemic reactions following immunization with acellular (DTaP) or whole-cell (DTwP) pertussis vaccine. 
Percent of children with stated reaction 
Reaction Dose 1 Dose 2 Dose 3 
DTaP DTwP p DTaP DTwP p DTaP DTwP p 
(n = 123) (n = 118) (n = 96) (n = 87) (n = 87) (n = 80) 
Local 
Redness 1 3 ns O 3 ns 1 4 ns 
Induration 3 15 <0.01 6 24 c 0.001 13 32 < 0.001 
9 21 co.01 Tenderness 5 11 ns 3 8 ns 
Anorexia 1 5 ns 5 6 ns 5 4 ns 
Vomiting 7 11 ns 12 10 ns 12 11 ns 
Restlessness 10 17 ns 7 8 ns 4 6 ns 
Irritability 18 24 ns 11 18 ns 9 12 ns 
Sleepiness 11 16 ns 6 11 ns 8 7 ns 
Crying 22 53 < 0.001 17 31 c0.01 17 27 4 .05  
Unusual cry 3 3 ns 2 1 ns 2 2 ns 
Fever 1 38" O 2 ns O 2 ns O 6 c0.01 
Systemic 
ns, not significant 
paired t-test. Inter-group comparisons were subjected to analy- 
sis of variance or the Kruskall-Wallis test, when indicated. 
Results 
Sample Size. A total of 291 infants were recruited 
into the study. Five of these children received the 
wrong vaccine at least once during the three-dose 
series and were excluded from the further analy- 
sis. Of the 286 infants who received the first dose 
and were retained for analysis (Table l ) ,  245 re- 
ceived the second dose and 216 received all three 
doses of the study vaccines. The vaccine groups 
were compared for factors such as age, gender, 
weight, height and village of origin, with no differ- 
ences being found. A similar analysis was per- 
formed for the evaluation of safety for which 
more than 75% of the children were seen after 
each dose. Comparisons also revealed no differ- 
ences between the groups in the immunogenicity 
results, in which only a sub-sample of the children 
were analysed because either parents refused to 
allow a blood sample to be collected or an insuf- 
ficient blood volume was collected. 
Clinical Reactions. As shown in Table 2, the fre- 
quency of observed adverse reactions for each 
dose in the DTaP group was generally equal to or 
lower than that in the DTwP group. Differences 
were significant for induration and crying after 
each dose, and for local tenderness and fever on- 
ly after the third dose. A significant positive trend 
was observed for local reactions in the DTaP 
group for induration only (p < O.OOl), and in the 
DTwP group for induration (p < OOOl), tenderness 
(p < 0.01) and fever (p < 0.05). No severe reactions 
were detected at the physicians' visits. Six deaths 
occurred within two months after injection, four 
Table 3 Geometric mean antibody titres after acellular and whole-cell pertussis vacche. 
CHO cell toxin 
neutralizationa 
Antibody 
to F H A ~  
Acellular vaccine 
prevaccine 
post-dose 2 
post-dose 3 
Whole-cell vaccine 
prevaccine 
post-dose 2 
post-dose 3 
~ 
n = 57 
5.1 
15.8' 
46.7 
n = 39 
4.9 
9.9 
88.1e 
n = 4 0  
0.45 
12.0e 
38.0d 
n = 28 
0.61 
1.95 
22.1 o 
aExpressed in reciprocal dilutions. 
bExpressed in EIA units per milliliter. 
cp < 0.05, dp c 0.01, ep < 0.001 compared with the other vaccine group for the same number of doses. 
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Table 4 Geometric mean antibody titres (expressed as international units per milliliter) after diphtheria, tetanus, polio type I 
and .III vaccine related to the type of pertussis vaccine Co-administered. 
Diphtheria Tetanus Polio Type I Polio Type III 
n GMT n GMT n GMT n GMT 
Acellular vaccine 
Prevaccine 10 0.045 12 0.028 42 6.47 ' 15 i .6b 
Post-dose 2 10 0.184 13 0.69ga 56 278.6 25 500.0 
Post-dose 3 7 0.303 9 1.23 57 739.6 20 1503.1b 
Whole-cell vaccine 
Prevaccine 9 0.021 11 0.033 39 5.32 15 5.26 
Post-dose 2 11 0.282 12 2.39 41 205.6 29 283.1 
Post-dose 3 7 0.296 6 2.48a 51 657.6 21 912.0 
ap < 0.01 
bp c 0.05 
in the DTwP group and two in the DTaP group. 
According to the verbal autopsy the causes of 
death were as follows (with vaccine and dose 
number): unknown (10 days after DTwPl), mal- 
aria and pneumonia (14 days after DTwP2), diar- 
rhea (41 days after DTwP3), diarrhea associated 
with protein energy malnutrition (57 days after 
DTwP3), meningitis (58 days after DTaPl), and di- 
arrhea (10 days after DTaP2). 
Immune Response. Pre-vaccine titres for FHA and 
PT were similar in the two groups.The DTaP vac- 
cine was associated with significantly higher anti- 
body titres to FHA after dose 2 and dose 3, and 
to PT after dose 2. In contrast, the mean PT- 
neutralizing antibody titre after dose 3 was signif- 
icantly higher in the DTwP group (Table 3). With 
both vaccines, there was a significant increase in 
both FHA and PT antibody titres after dose 3 
compared with dose 2. Seroconversion rates were 
almost identical in the two vaccine groups: 95% 
and 93% for PT in the DTaP and DTwP groups, 
respectively, and 95% and 93% for FHA. 
Antibody titres for diphtheria, tetanus and polio 
types I and III are shown in Table 4. Diphtheria 
antibody titres were similar in the two vaccine 
groups. Protective levels were obtained in all sub- 
jects in both groups. Although the tetanus anti- 
body titres were comparable before vaccination, 
rises in titres were significantly higher in the 
DTwP group; however, seroprotection rates 
against tetanus were 100% in both groups. Anti- 
body titres for polio virus types I and III were sim- 
ilar in the two vaccine groups but titres for polio 
virus type III were significantly lower before vac- 
cination in DTaP recipients than in DTwP recip- 
ients and higher after dose 3. Nevertheless, sero- 
protection rates were 100% in both groups after 
two doses. The seroconversion rates in infants who 
had pre-vaccination titres below the seroprotective 
level were 100% in both groups after two doses. 
Discussion 
The present study was performed in a different 
setting from two other immunogenicity and safe- 
ty studies which used slightly different immuniza- 
tion regimens to compare the same acellular per- 
tussis vaccine to other whole-cell pertussis vac- 
cines (13, B. Auerbach et al.: Congress of the 
Society for Pediatric Research, Washington D.C., 
1989, abstract). The results confirm the decreased 
reactogenicity of the acellular vaccine compared 
to the whole-cell vaccine. In the present study, an 
increased rate of crying and local induration was 
observed significantly more frequently after each 
dose in recipients of DTwP than of DTaP vaccine. 
Six deaths occurred within two months of vacci- 
nation, four in the DTwP group and two in the 
DTaP group. As in most parts of sub-saharan 
Africa, there is very high infant mortality in the 
study area, and the number and causes of death 
are thus not unexpected. The verbal autopsy 
method of assessing the cause of death, developed 
for large population studies, lacks precision in de- 
termining the cause of individual deaths. No seri- 
ous events associated with DTwP vaccination 
were observed. Studies with this new generation 
of vaccines in a larger population are needed to 
monitor for adverse effects that are less frequent 
or more severe. 
All children had protective levels of antibody 
against diphtheria, tetanus and polio virus. Diph- 
theria and polio (types I and III) antibody titres 
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in the DTaP group were similar to or higher than 
those observed in the DTwP group, suggesting that 
the acellular pertussis vaccine does not interfere 
with the other antigens. Although the tetanus an- 
tibody titres were lower in the DTaP group than 
in the DTwP group, the response of every child 
was well above the protective level. An adjuvant 
effect of whole-cell pertussis vaccine on the teta- 
nus and diphtheria response has been suggested 
but could be lacking with the acellular vaccine (14, 
15). 
Both vaccines produced a vigorous antibody re- 
sponse to PT and FHA. After the third dose, the 
acellular vaccine induced higher FHA antibody ti- 
tres than the whole-cell vaccine, whereas the lat- 
ter induced higher PT antibody titres. The same 
batch of acellular pertussis vaccine (lot S2112) was 
used in a large multicenter study comparing 13 
acellular pertussis vaccines and two US whole-cell 
vaccines, allowing comparison of results between 
the two studies (16-18).The assays used in the two 
studies were slightly different and the values ob- 
tained are therefore not directly comparable. 
Nonetheless, the PT-neutralization test results 
were very similar: prevaccination and post-third 
dose geometric mean titres were 5.1 and 46.7, re- 
spectively, in this study, compared with 3.8 and 43 
in the NIAID study (7). Our data do not suggest 
that there is a better response in black children per 
se, as suggested in the NIAID study (7). 
Comparison of the FHA antibody titres is not pos- 
sible since our assay was developed in 1989, prior 
to standardization. In the NIAID study, the 
present acellular pertussis vaccine induced PT 
and FHA antibody titres comparable with those 
induced by the other acellular pertussis vaccines 
tested, and for both antigens the titres were equal 
to or higher than those obtained with either of the 
US licensed whole-cell pertussis vaccines tested. 
The high PT antibody titres obtained in this study 
with the whole-cell pertussis vaccine confirm that 
it is appropriate as control vaccine in clinical 
trials in a developing country where it is routine- 
ly used. 
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